Flora Growth Corp(FLGC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -32.46 | Insider Own | 20.08% | Shs Outstand | 1.1M | Perf Week | 32.2% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 82.24% | Insider Trans | - | Shs Float | 0.8M | Perf Month | 22.94% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | -0.39 | Inst Own | 1.5% | Short Float | 2.7% | Perf Quarter | -23.31% |
| Income | -0.02B | P/S | 0.19 | EPS this Y | 92.78% | Inst Trans | -0.63% | Short Ratio | 0.35 | Perf Half Y | -64.69% |
| Sales | 0.05B | P/B | 0.1 | EPS next 5Y | - | ROA | -25.03% | Short Interest | 0.02M | Perf YTD | 42.97% |
| Book/sh | 91.18 | P/C | 0.71 | EPS past 3/5Y | 41.53% -14.88% | ROE | -37.38% | 52W High | -80.96% ($47.00) | Perf Year | -72.08% |
| Cash/sh | 12.64 | P/FCF | - | Sales past 3/5Y | 87.83% - | ROIC | -24.44% | 52W Low | 52.73% ($5.86) | Perf 3Y | -95.84% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 53.82% | Gross Margin | -6.07% | Volatility(W/M) | 27.22% 13.48% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | -0.01 | Sales Y/Y TTM | -22.6% | Oper. Margin | -25.86% | ATR (14) | 1.36 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.79 | EPS Q/Q | 17.9% | Profit Margin | -32.14% | RSI (14) | 57.65 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.08 | Sales Q/Q | -21.8% | SMA20 | 26.61% ($7.07) | Beta | 1.96 | Target Price | $11 |
| Payout | - | Debt/Eq | 0.05 | Earnings | 2025/11/5 | SMA50 | 15.04% ($7.78) | Rel Volume | 4.57 | Prev Close | $10.97 |
| Employees | 76 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -131.46% -22.02% | SMA200 | -51.02% ($18.27) | Avg Volume(3M) | 0.06M | Price | $8.95 |
| IPO | 2021/5/11 | Option/Short | No/Yes | Trades | 1910 | Volume | 293,526 | Change | -18.41% |
Flora Growth Corp. (FLGC) is a pharmaceutical and biohealth company that cultivates, processes, and distributes medical and consumer cannabis products on the global market, and specializes in supplying specialized raw material inputs for therapeutic medicines.
Over the past 1 year, on the lower side
81% below its 1-year high.
Traded more than usual. That is 457% of its average volume.
FLGC has a sound balance sheet but weak earning power
Of every $100 in sales, $25.86 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +92.8% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $19. Peers typically go for $204.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -95.8%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 1.5%.
Tap to view numbers
It ranks #73 of 84 in the industry
Based on market cap of $9M.
FAQ
What kind of company is FLGC?
FLGC belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of FLGC?
The market cap of FLGC is approximately $9M, ranking 5,507 within its sector.
What is the 52-week high and low for FLGC?
FLGC has recorded a 52-week high of $47.00 and a low of $5.86.
